Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 15Kisspeptin (KP-10) literaturebiorxiv-preprint · Observational2023

Inactivating PLEKHA6 Mutations Cause Idiopathic Hypogonadotropic Hypogonadism Through Impaired Kisspeptin Secretion

PLEKHA6 has been identified as a novel gene linked to idiopathic hypogonadotropic hypogonadism, with variants impairing kisspeptin secretion. Further research is needed to understand the clinical relevance of these findings.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the kisspeptin (kp-10) corpus
1
Preclinical
12
Observational · this one
0
Open-label
2
Randomised
0
Reviews

Summary and findings

This study investigated the genetic basis of idiopathic hypogonadotropic hypogonadism (IHH) by analyzing exome and genome sequencing data from 1,822 patients. The researchers identified 18 distinct PLEKHA6 variants in 24 patients, which were associated with impaired kisspeptin secretion. The findings suggest a novel role for PLEKHA6 in the regulation of kisspeptin secretion.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=18222023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>ABSTRACT</h4> <h4>Purpose</h4> Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by impaired reproductive maturation, and approximately half of all cases lack an identified genetic cause. We investigated the genetic basis of IHH in two large cohorts to identify novel disease-causing genes. <h4>Methods</h4> We analyzed exome and genome sequencing data from 1,822 patients with IHH from two independent cohorts. Rare variants were filtered using pedigree-informed inheritance models. PLEKHA6 expression in the postmortem human hypothalamus were tested at the mRNA and protein level. Functional studies assessed kisspeptin secretion in cell-based assays. <h4>Results</h4> We identified 18 distinct PLEKHA6 variants in 24 patients from 20 unrelated families (1.3% of cohort). Variants segregated with disease under autosomal recessive and autosomal dominant (with variable penetrance) inheritance patterns. PLEKHA6 was robustly expressed in the hypothalamus and showed clear colocalization with neurokinin B, which served as the marker for the GnRH pulse generator. Functional studies demonstrated that patient variants significantly impaired kisspeptin secretion. <h4>Conclusion</h4> PLEKHA6 is a novel IHH gene and the first reported regulator of kisspeptin secretion from the kisspeptin-neurokinin B-dynorphin (KNDy) neurons, which have recently been established as the GnRH pulse generator. These findings establish impaired kisspeptin release as a new disease mechanism in IHH and highlight the critical role of neuropeptide trafficking in reproductive function.

Background

This paper addresses the genetic underpinnings of idiopathic hypogonadotropic hypogonadism (IHH), a condition characterized by impaired reproductive maturation. Prior research has identified various genetic causes of IHH, but approximately half of the cases remain unexplained. Understanding the genetic basis of IHH is crucial for developing targeted interventions and enhancing reproductive health.

Methods

The study analyzed exome and genome sequencing data from 1,822 patients with IHH across two independent cohorts. Rare variants were filtered using pedigree-informed inheritance models. PLEKHA6 expression was assessed in postmortem human hypothalamus at both the mRNA and protein levels, while functional studies evaluated kisspeptin secretion in cell-based assays.

Results

The primary finding was the identification of 18 distinct PLEKHA6 variants in 24 patients, representing 1.3% of the cohort. These variants were found to segregate with the disease under both autosomal recessive and dominant inheritance patterns. PLEKHA6 expression was confirmed in the hypothalamus, and functional studies indicated that the patient variants significantly impaired kisspeptin secretion.

Interpretation

The findings of this study suggest that PLEKHA6 is a novel gene associated with IHH and plays a critical role in kisspeptin secretion. While the association is statistically significant, the clinical implications of these findings need to be further explored. Potential confounds include the reliance on genetic data from a specific population and the need for additional functional studies to confirm the role of PLEKHA6 in kisspeptin regulation.

Key findings

  • 18 distinct PLEKHA6 variants identified in 24 patients from 20 unrelated families (1.3% of cohort).
  • Variants segregated with disease under autosomal recessive and autosomal dominant inheritance patterns.
  • PLEKHA6 was robustly expressed in the hypothalamus.
  • Functional studies demonstrated that patient variants significantly impaired kisspeptin secretion.

Limitations

  • 1.3% of cohort with identified variants may limit generalizability.
  • Study relies on genetic data from specific populations.
  • Functional implications of variants require further investigation.

Elsewhere in the Kisspeptin (KP-10) corpus

BFrom subtle symptoms to disclosure: Communication in violence detection in primary care.The European journal of general practice · 2026 · 25/326 patients disclosed experiences of violence.HumanDReduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.Human vaccines & immunotherapeutics · 2026 · 10% reduction in cross-conserved T cell epitope content.reviewCVirulence attenuation in ST11-K64 &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt; explains its divergent clinical manifestation from ST23-K1.Virulence · 2026 · 157 (18.5%) of 847 clinical Klebsiella pneumoniae isolates were identified as hv-CRKP.AnimalCHigh-Fat Diet Induces Epigenetic and Metabolic Changes in Kisspeptin Neurons in Association with Obesity and Male Secondary Hypogonadismbiorxiv-preprint · 2025 · Not reported in abstract.AnimalANVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2026 · n=176 · 50% neutralization titers against strain XBB.1.16 boosted by 3.2-fold in monovalent mRNA, 4.1-fold in bivalent mRNA, and 1.6-fold in NVX-CoV2373 at day 28.HumanBSafety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies.Human vaccines & immunotherapeutics · 2026 · Not reported in abstract.review